Outdated headlines have created confusion around testosterone therapy safety. The evidence is clear: when properly diagnosed, dosed, and monitored by a clinical team, TRT is both safe and effective. Here's what the science actually says — and how we ensure your safety at every step.
Much of the fear around testosterone therapy stems from retracted studies and misinterpreted data. Here's what large-scale, peer-reviewed research actually shows.
Testosterone therapy causes heart attacks
Large-scale studies including the TRAVERSE trial (2023, 5,246 men) found no increased cardiovascular risk with testosterone therapy in men with hypogonadism. The AUA and Endocrine Society support TRT when properly monitored.
TRT causes prostate cancer
Current evidence does not support a causal link between testosterone therapy and prostate cancer. The Endocrine Society guidelines confirm that TRT is not contraindicated in men without active prostate cancer.
Testosterone therapy causes blood clots
When properly monitored with regular hematocrit testing, the risk of polycythemia (elevated red blood cells) is manageable. Therapeutic phlebotomy and dose adjustments keep levels in safe ranges.
Once you start TRT, you can never stop
While long-term TRT can suppress natural production, protocols exist to taper off with HCG or selective estrogen receptor modulators (SERMs) to support recovery of the hypothalamic-pituitary-gonadal axis.
Safety isn't an afterthought — it's built into every step of our testosterone therapy process, from initial evaluation through ongoing monitoring.
350+ biomarker panel including total & free testosterone, SHBG, estradiol, LH, FSH, PSA, hematocrit, lipid subfractions, liver & kidney function, and cardiovascular risk markers before any treatment begins.
Every protocol is designed and supervised by our expert team of health care providers. No online questionnaires, no cookie-cutter dosing — just evidence-based medicine tailored to your unique physiology.
Regular follow-up bloodwork at 6–8 week intervals during optimization, then quarterly. We track hematocrit, PSA, estradiol, liver enzymes, lipids, and cardiovascular markers continuously.
Estrogen management with aromatase inhibitors when needed, hematocrit monitoring with therapeutic phlebotomy protocols, and cardiovascular risk reassessment at every visit.
Regular bloodwork is the cornerstone of safe testosterone therapy. We track these critical markers at every follow-up to catch and address any changes early.
The relationship between testosterone and cardiovascular health has been one of the most debated topics in men's medicine. Early concerns were driven by a 2010 TOM trial and a retracted 2014 JAMA study — both with significant methodological limitations.
The TRAVERSE trial (2023) — the largest randomized, placebo-controlled study of testosterone therapy to date — followed 5,246 men aged 45–80 with hypogonadism and pre-existing cardiovascular risk for a median of 33 months. The conclusion: testosterone therapy did not increase the incidence of major adverse cardiovascular events compared to placebo.
Furthermore, low testosterone itself is independently associated with increased cardiovascular mortality, metabolic syndrome, insulin resistance, and visceral obesity — all of which are risk factors for heart disease. Restoring testosterone to physiological levels may actually be cardioprotective.
At ReGenesis, we monitor cardiovascular biomarkers including ApoB, Lp(a), hs-CRP, and hematocrit throughout treatment to ensure your cardiovascular risk profile remains optimal.
We believe testosterone therapy should never be prescribed without rigorous diagnostics, clinical oversight, and a commitment to ongoing safety monitoring.
Windermere Plaza
213, 5540 Windermere Blvd, Edmonton, AB T6W 2Z8
Silk Touch
1102, 8561 8A Ave SW, Calgary, AB T3H 0V5